These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19389066)

  • 1. In vitro activity of voriconazole against Mexican oral yeast isolates.
    Sánchez Vargas LO; Eraso E; Carrillo-Muñoz AJ; Aguirre JM; Gaitán-Cepeda LA; Quindós G
    Mycoses; 2010 May; 53(3):200-3. PubMed ID: 19389066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.
    Burn AK; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; McCarthy DI; Rinaldi MG; Redding SW
    J Clin Microbiol; 2004 Dec; 42(12):5846-8. PubMed ID: 15583322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Candida isolates among HIV-infected subjects in Nigeria.
    Nweze EI; Ogbonnaya UL
    J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
    Swinne D; Watelle M; Van der Flaes M; Nolard N
    Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
    Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
    Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
    Lee SC; Lo HJ; Fung CP; Lee N; See LC
    J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
    Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
    Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.
    Ruhnke M; Schmidt-Westhausen A; Trautmann M
    Antimicrob Agents Chemother; 1997 Mar; 41(3):575-7. PubMed ID: 9055995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigation of in vitro activities of fluconazole, itraconazole and voriconazole against clinical isolates of Blastoschizomyces capitatus (Geotrichum capitatum) by two different methods].
    Sancak B; Alp S; Hasçelik G; Arikan S
    Mikrobiyol Bul; 2009 Apr; 43(2):269-76. PubMed ID: 19621612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV-infected patients.
    Traboulsi RS; Mukherjee PK; Ghannoum MA
    Int J Antimicrob Agents; 2008 Mar; 31(3):272-6. PubMed ID: 18242063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
    Chávez M; Bernal S; Valverde A; Gutierrez MJ; Quindós G; Mazuelos EM
    J Antimicrob Chemother; 1999 Nov; 44(5):697-700. PubMed ID: 10552989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and antifungal susceptibility of Candida parapsilosis complex isolates collected from oral cavities of HIV-infected individuals.
    Moris DV; Melhem MSC; Martins MA; Souza LR; Kacew S; Szeszs MW; Carvalho LR; Pimenta-Rodrigues MV; Berghs HAM; Mendes RP
    J Med Microbiol; 2012 Dec; 61(Pt 12):1758-1765. PubMed ID: 22956748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
    Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
    Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):27-34. PubMed ID: 19679232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.